Cancer epigenomics and beyond: Advancing the precision oncology paradigm

3Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

Abstract

How cancers are characterized and treated has evolved over the past few decades. Major advances in genomics tools and techniques have revealed interlinked regulatory pathways of cancers with unprecedented detail. Early discoveries led to success with rationally targeted small molecules and more recently with immunomodulatory agents, setting the stage for precision oncology. However, drug resistance to every agent has thus far proven intractable, sending us back to fill the gaps in our rudimentary knowledge of tumor biology. Epigenetics is emerging as a fundamental process in every hallmark of cancer. Large-scale interrogation of the cancer epigenome continues to reveal new mechanisms of astounding complexity. In this review, I present selected experimental and clinical examples that have shaped our understanding of cancer at the molecular level. Translation of our collective erudition into revolutionary diagnostic and treatment strategies will advance the precision oncology paradigm.

Cite

CITATION STYLE

APA

Lee, D. Y. (2020). Cancer epigenomics and beyond: Advancing the precision oncology paradigm. Journal of Immunotherapy and Precision Oncology. Innovative Healthcare Institute. https://doi.org/10.36401/JIPO-20-18

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free